Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7663498 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Participants will receive RO7663498. |
| Cohort 2 | EXPERIMENTAL | Participants will receive RO7663498. |
| Cohort 3 | EXPERIMENTAL | Participants will receive RO7663498. |
| Cohort 4 | EXPERIMENTAL | Participants will receive RO7663498. |
| Name | Type | Description |
|---|---|---|
| RO7663498 | DRUG | Participants will receive RO7663498 as per the schedule defined in the protocol. |
Inclusion Criteria: General Inclusion Criteria * Diagnosis of Diabetes Mellitus (DM) (Type 1 or Type 2), as defined by the World Health Organization and/or American Diabetes Association Ocular Inclusion Criteria for the Study Eye * BCVA score at screening of \>= 19 letters in study eye using Ear...
RO7663498 is an investigational small molecule being studied for the treatment of diabetic retinopathy, a complication of diabetes that affects the eyes. It is administered via intravitreal injection directly into the eye. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
RO7663498 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded on the OTC market under the ticker RHHBY. The company is conducting clinical trials to evaluate the safety, tolerability, and pharmacokinetics of this investigational drug in patients with diabetic retinopathy.
RO7663498 is in Phase 1 clinical development. This early-stage trial is designed to assess the safety, tolerability, and pharmacokinetics of the drug following intravitreal administration in participants with diabetic retinopathy. The study is currently recruiting participants and has not yet progressed to later-phase trials.
RO7663498 is being evaluated in a single Phase 1 clinical trial registered as NCT07588100. This study is investigating the safety, tolerability, and pharmacokinetics of RO7663498 following intravitreal administration in participants with diabetic retinopathy. The trial is currently recruiting participants in the United States and aims to enroll 30 patients aged 18 years and older.
RO7663498 is administered via intravitreal injection, meaning it is injected directly into the vitreous humor of the eye. This route of administration is commonly used for ophthalmic drugs to deliver the medication locally to the retina. The ongoing Phase 1 trial is evaluating this delivery method in patients with diabetic retinopathy.